Maxcyte (MXCT) Revenue (2020 - 2026)

Maxcyte (MXCT) has reported Revenue for 7 consecutive years, with $7.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue fell 14.53% year-over-year to $7.3 million in Q2 2026; TTM through Jun 2026 was $31.1 million, a 13.15% decrease from a year earlier, with the FY2025 full-year figure at $33.0 million, down 14.5% from the prior year.
• Revenue was $7.3 million for Q2 2026 at Maxcyte, down from $9.7 million in the prior quarter.
• Over five years, Revenue peaked at $15.7 million in Q4 2023 and troughed at $6.8 million in Q3 2025.
• A 5-year average of $9.7 million and a median of $9.3 million in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 78.41% in 2022 and tumbled 44.51% in 2024, its largest moves.
• Over 5 years, Revenue stood at $12.4 million in 2022, then increased by 26.1% to $15.7 million in 2023, then plunged by 44.51% to $8.7 million in 2024, then declined by 16.02% to $7.3 million in 2025, then declined by 0.4% to $7.3 million in 2026.
• The last three Revenue figures came in at $7.3 million (Q2 2026), $9.7 million (Q1 2026), and $7.3 million (Q4 2025), per Business Quant data.